Once-yearly Aclasta® approved in EU to treat osteoporosis

-
Steroids, widely used to treat inflammatory conditions, can cause bone loss and increase risk of fractures in up to 50% of patients on long-term therapy[1]
European approval based on data showing Aclasta better at increasing bone mass than oral risedronate, a current established therapy[2],[3]
Clinical trial results also reaffirm efficacy and safety of Aclasta, used in more than 500,000 patients worldwide since launch in 2007[4],[5]
Approval is fifth indication for once-yearly Aclasta, already approved worldwide to treat postmenopausal osteoporosis[6]